Abstract 2693
Background
The PROCHE [Programme for optimisation of the chemotherapy network] initiative is an innovative oncology-monitoring program designed to reduce patient waiting time and chemotherapy wastage, ultimately improving patient care. A nurse calls patients 48 hours before anticancer treatment at the daily hospital to anticipate chemotherapy preparation.
Methods
Primary objective was to evaluate the incidence of different symptoms reported by grade (NCI-CTC AE: from 0 to 4) prospectively collected from 2008 to 2016. Secondary objective compared the 2009-2016 patients to the control cohort (2008 period) quantified using Mantel-Haenszel khi2 and exact p-values.
Results
From January 2009 to December 2016, 3012 patients were enrolled in the program, representing 36 803 questionnaires completed over the whole period. Main adverse events (AE) were collected and compared to the control cohorts (2008, n = 513), resulting in a significant decrease in majority of topics. Global incidence comparison is presented in table 1, with the p-value according to khi2 test. Details of severity levels scores using NCI CTC-AE V4.0, will be reported at ESMO meeting. For some of the toxicities, severe or life threatening toxicities (grades 3-4) were higher in the PROCHE cohort, while global incidence decreased.rnTable:
1542PD
rn| Adverse Event | 2008 (%) | 2009-2016 (%) | p-value | rn
|---|---|---|---|
| Fatigue | rn82.4 | rn62.01 | rnConclusionsThe PROCHE initiative resulted in adverse events decrease and improved patient quality of care and improved hospital as well as pharmacy efficacy. Clinical trial identificationLegal entity responsible for the studyFlorian Scotté FundingNone DisclosureF. Scotté: Roche, Vifor, MSD, Teva, Norgine, Prostrakan, Leo pharma, Janssen, Hospira, Boehringer, Sanofi, Amgen, Pierre Fabre Oncologie, Tesaro. C. Thibault: Roche. All other authors have declared no conflicts of interest. Resources from the same sessionSupportive and palliative care: Invited Discussant 1542PD, 1387PD and LBA54Presenter: Andreas Charalambous Session: Supportive and palliative care Resources: Slides Webcast Supportive and palliative care: Invited Discussant 1388PD, 1389PD, 1544PD, 1545Pd and 1546PDPresenter: Pedro Gascon Session: Supportive and palliative care Resources: Slides Webcast Supportive and palliative care: Invited Discussant 1547PD, 1548PD and 1549PDPresenter: Bernardo Rapoport Session: Supportive and palliative care Resources: Slides Webcast 3599 - Cancer cachexia (CAX), anorexia and muscle wasting (sarcopenia) assessment in non-small cell lung cancer (NSCLC): an observational study in 531 patientsPresenter: Didier Debieuvre Session: Supportive and palliative care Resources: Abstract Slides Webcast 4296 - Pre-Chemotherapy Nutritional status and chemotherapy response: An Observational Study.Presenter: Vijay Agarwal Session: Supportive and palliative care Resources: Abstract Slides Webcast 2325 - Fosaprepitant reduces the impact of nausea on daily function during five weeks of chemo-radiotherapy – a sub-study of the GAND-emesis trialPresenter: Christina Ruhlmann Session: Supportive and palliative care Resources: Abstract Slides Webcast 1697 - CTCA toxicity scoring and EORTC Quality of Life Questionnaire – a comparison of physicians’ and patients’ scoring of toxicity in the "Panther trial"Presenter: Yvonne Brandberg Session: Supportive and palliative care Resources: Abstract Slides Webcast Supportive and palliative care: Invited Discussant 1386O and 1539OPresenter: Stein Kaasa Session: Supportive and palliative care Resources: Slides Webcast Supportive and palliative care: Invited Discussant 1540O and 1422OPresenter: Karin Jordan Session: Supportive and palliative care Resources: Slides Webcast 4492 - Reproductive potential and performance of fertility-preserving procedures in BRCA mutation-positive (BRCA+) breast cancer (BC) patients (pts)Presenter: Matteo Lambertini Session: Supportive and palliative care Resources: Abstract Slides Webcast This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used. For more detailed information on the cookies we use, please check our Privacy Policy.
|